Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.
Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, DiMaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi S, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M
Melanoma, Version 4.2014 Featured Updates to the NCCN Guidelines
Journal of the National Comprehensive Cancer Network (2014) 12:621-629.
Abstract
The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.
Note
Publication Date: 2014-05-01.
PMCID: No NIH funding
Back
Last updated on Thursday, November 02, 2017